NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Core Viewpoint - NanoViricides, Inc. is advancing a dual-track clinical development strategy for its drug NV-387, targeting both MPox and a range of respiratory viral infections, including Influenza, Coronaviruses, and RSV [1] Group 1 - The analyst research report highlights the rapid clinical development strategy of NanoViricides [1] - NV-387 is positioned to address multiple viral infections, indicating a broad therapeutic potential [1] - The report was published by Proactive Investors, emphasizing the company's strategic direction [1]